BiotechTube
Imvaria

Imvaria

San Francisco, United States· Est.
imvaria.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $27.4M

Overview

Imvaria, founded in 2019 by physician-engineers from Google and Stanford, is a private, commercial-stage diagnostics company based in Berkeley, California. It has developed Fibresolve, the first FDA-authorized AI diagnostic tool for IPF/ILD, and is expanding its platform to other areas like lung cancer through a strategic collaboration with Mayo Clinic. The company operates a Digital Biomarker Lab, leveraging machine learning to create software-only biomarkers from complex clinical data, positioning it at the intersection of AI, radiology, and precision diagnostics.

PulmonologyOncology

Technology Platform

AI-driven digital biomarker platform (Digital Biomarker Lab) that uses machine learning and deep learning to analyze multi-modal clinical data (e.g., CT images, text, numeric values) to create non-invasive diagnostic and prognostic software tools.

Funding History

2
Total raised:$27.4M
Series A$24M
Seed$3.4M

Opportunities

The global need for non-invasive, accurate diagnostic tools in complex diseases like ILD and lung cancer represents a massive market.
Expansion of its AI platform into new disease areas (oncology, cardiology, etc.) through strategic partnerships can drive significant long-term growth.
The shift towards value-based care and digital health adoption in healthcare systems creates a favorable environment for AI-powered tools that improve efficiency and outcomes.

Risk Factors

Regulatory pathways for Software as a Medical Device (SaMD) are complex and vary by region, posing a barrier to market entry and expansion.
Clinical adoption and securing reimbursement from payers for novel AI diagnostics are significant commercial challenges.
The company operates in a highly competitive and fast-moving space with numerous well-funded entrants, risking technological obsolescence or market saturation.

Competitive Landscape

Imvaria competes in the rapidly growing AI medical imaging market. In ILD, competitors include other AI radiology startups (e.g., Avicenna.ai, Aidoc) and research consortia developing similar algorithms. In the broader digital biomarker and oncology AI space, competition is intense, involving large tech companies (Google, IBM Watson), diagnostic giants (Roche, Philips), and numerous specialized AI startups. Imvaria's first-mover FDA status in IPF/ILD and its Mayo Clinic partnership are key differentiators.

More companies in Diagnostics & Precision Medicine →More companies in United States →